Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit hepatitis C virus replication to be licensed for use in conjunction with pegylated interferon and ...

Both the boceprevir and telaprevir phase III studies used the COBAS TaqMan HCV RNA assay, version 2.0 (Roche), with a LLOD of 10 IU/mL and a LLOQ of 25 IU/mL. Eligibility for RGT was based on the ...

Their early research, posted online in September 2020, demonstrated that a hepatitis C drug, boceprevir, slotted reasonably ...

Boceprevir is a protease inhibitor, prescribed for chronic hepatitis C. The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is ...

The new trial tested the effect of peginterferon and ribavirin with or without boceprevir, an NS3 oral inhibitor, in a cohort of treatment-naive patients. Patients who received boceprevir had ...

Paricalcitol 1mcg, 2mcg; soft gel caps. Take without regard to food. <10yrs: not established. 10–16yrs: CKD Stages 3/4: initially 1mcg 3 times weekly (no more often than every other day).

Most DAAs are only available as part of a combination pill. The first-generation hepatitis C protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivo), were approved in 2011. They were only ...

Vertex took a hit from investors after Schering presented data on its small molecule, boceprevir, indicating it achieved undetectable HCV RNA in up to 79% of patients (up from 50% expected cure ...

Cyclosporine (modified) 100mg/mL; contains alcohol. Give consistently with regard to meals and time of day. ≥18yrs: 1.25mg/kg twice daily; may increase by 0.5–0.75mg/kg per day after 8 weeks ...

HCV, a small ribonucleic acid (RNA) virus causing hepatic diseases, is targeted by PIs like asunaporevir, telaprevir, and ...